Cerevel Therapeutics Holdings, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Cerevel Therapeutics Holdings, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$143M, a 43.3% decline year-over-year.
  • Cerevel Therapeutics Holdings, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$490M, a 24.2% decline year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2023 was -$447M, a 21.6% decline from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2022 was -$368M, a 67.1% decline from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2021 was -$220M, a 47.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$447M -$79.4M -21.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$368M -$148M -67.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$220M -$71M -47.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$149M -$65.7M -78.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 -$83.5M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.